Geko Device Improves Care After Kidney Transplantation

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

In a published study, a team from Lawson Health Research Institute (LHSC), in Ontario Canada, has found that a simple medical device can reduce swelling after kidney transplantation.

geko device, (wearable) manufactured by UK-based, Sky Medical Technology Ltd and distributed in Canada by Trudell Healthcare Solution Inc., is a small muscle pump activator that significantly increases blood flow via painless electrical pulses. Patients using the device following kidney transplantation experienced shorter hospital stays and reduced surgical site infections by nearly 60 percent.

Kidney and simultaneous pancreas-kidney transplantations can significantly reduce mortality and improve the quality of life for patients with end-stage renal disease. Dr. Alp Sener, Lawson Scientist and Transplant Surgeon in the Multi-Organ Transplant Program at LHSC, who lead the study explains: “After surgery, many of these organ recipients require a longer hospital stay due to delayed kidney function, infection, lack of mobility or edema.”

Edema is swelling caused by excess fluid trapped in the body’s tissues which can impact wound healing. The current standard of care for managing lower-limb edema and improving blood flow in Canada healthcare systems recommend thrombo-embolic-deterrent (TED) stockings, used alongside a boot-like cuff that compresses the leg to increase blood flow, called intermittent pneumatic compression (IPC). Both can be uncomfortable to wear, and IPC can inhibit early mobility and disrupt sleep after surgery.

In a randomized controlled clinical trial spanning two years, 221 transplant recipients at LHSC have prescribed either TED stocking and IPC or the geko™ device for six days after surgery. The research team found that wearing the device increased urine output by 27 percent and lowered weight gain by over a kilogram. With more urine produced and less fluid retention, patients experienced 31 percent less swelling and the duration of costly hospitalization was shortened by more than one day after kidney transplantation, compared to the standard of care.

A 60 percent reduction in wound infection rates was a striking observation. “Transplant patients are at a higher risk of infection due to the immunosuppressant medications needed after surgery,” explains Dr. Sener, who is also the President of the Urologic Society for Transplantation and Renal Surgery, a global organization affiliated with the American Urological Association. “Reducing infection means a much better outcome for the patient and considering that recent data shows wound infections can cost the health care system thousands of dollars per person, it’s a win-win situation.”

Some of the study participants wore pedometers to track their steps, and those using the geko™ device also had improved mobility after surgery. The team suspects this may be due to reduced swelling which could improve ease and comfort when moving.

Dr. Sener adds: “The study results have been both surprising and exciting. Not only have we cut down wound infection rates, but we have also seen a considerable improvement in the new organ’s function following transplantation. Patients reported feeling more satisfied with the transplant process and are more mobile.”

The geko™ device has been adopted into the care pathway and is now being offered to patients at LHSC in recovery after receiving a new kidney.

Ruben Garcia, 68 years old, recently received a new kidney from his daughter, Ruby, who was a match as a living kidney donor. Following his surgery, Garcia found it difficult to get out of bed due to the pain and swelling, and the function of his new kidney was very low. “My surgeon explained in very simple terms that it was as if my new kidney wasn’t awake yet,” describes Garcia.

Dr. Sener recommended that Garcia use the geko™ device to help stimulate blood flow in a way that is similar to walking. Garcia was soon able to sit up on a chair and by the next day he was walking. “My kidney woke up and started working again! I could feel the device working and it was comfortable to wear, almost like a massage for my legs. I’m very grateful for the care that I received.”

Dr. Sener adds: “Using a muscle pump activator, like the gekoTM device, could be a game-changer for other procedures like orthopedic implants, where wound infection can have disastrous consequences, or in surgeries where wound infections are more common, such as in cancer and intestinal surgery.”

The geko™ device is non-invasive, self-adhering, battery-powered and recyclable. It generates neuromuscular electro-stimulation and unparalleled systemic blood flow that equates to 60 percent of that achieved by walking. Pain-free muscle contraction compresses deep veins in the lower legs to create increased blood flow in these vessels and return blood to the heart.

George Baran, Director of Sky Medical Technology Ltd, concludes: “The results of the study provide further evidence that the geko™ device is an effective treatment option that can improve outcomes for patients and help them return home sooner while reducing costs for healthcare systems.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles